Science

May 25, 2025, 11:41

Myeloma Paper of the Day, May 25th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of real world outcomes with elotuzumab-based therapies for relapsed and refractory myeloma finds median PFS for EPd was 4.8 months and for ERd was 17.28 months; median OS 2.55 and was 5.64 years, respectively.”

Title: Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

Authors: Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca, Nelson Leung, Prashant Kapoor, Morie Gertz, Francis Buadi, Angela Dispenzieri, Jamie Elliott, Andre Fernandez, Caitlin Flott, Asher A. Chanan-Khan, Vivek Roy and Sikander Ailawadhi.

You can read the Full Article in Blood Cancer Journal.

More posts featuring Robert Orlowski.

Andre Fernandez Angela Dispenzieri Asher A. Chanan-Khan Blood Cancer Journal Caitlin Flott cancer Francis Buadi Hanna Sledge Jamie Elliott Leif Bergsagel Morie Gertz Myeloma Myeloma Paper of the Day Nelson Leung OncoDaily Oncology Prashant Kapoor Rafael Fonseca Ricardo D. Parrondo Robert Orlowski RRMM Saurav Das Sikander Ailawadhi Vivek Roy

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply